Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
songling xuemaikang
- Development stage
- Phase 4
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Songling Xuemai Kang is a standardized Traditional Chinese Medicine (TCM) preparation developed by Chengdu Kanghong Pharmaceutical. It is primarily indicated for the treatment of primary hypertension (Grade 1-2) and associated symptoms such as dizziness, headache, and insomnia. The formulation is composed of extracts from *Pinus massoniana* (pine needles), *Pueraria lobata* (kudzu root), and pearl powder. Clinical evidence suggests that Songling Xuemai Kang is non-inferior to conventional antihypertensives like losartan potassium in reducing diastolic blood pressure. Beyond hypertension, it is being investigated for neuroprotective effects in cerebral small vessel disease (CSVD), where it may reduce neuronal apoptosis and alleviate ischemia-reperfusion injury, as well as for the management of ventricular premature contractions and dyslipidemia.
- Brand names
- Songling Xuemai Kang松龄血脉康
- Other names
- Songling Xuemaikang CapsuleSLXMKC松龄血脉康胶囊
02
Targets
ESR1 (ERα)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)ABCB1 (P-glycoprotein)NF-κBCACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on songling xuemaikang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on songling xuemaikang.